Thumbnail Image
Publication

New developments in the treatment of postmenopausal breast cancer.

Howell, Anthony
Citations
Altmetric:
Abstract
In recent years, new agents have challenged tamoxifen as the standard endocrine therapy for postmenopausal breast cancer. This article reviews developments with regard to the third-generation aromatase inhibitors (AIs)--anastrozole, letrozole and exemestane--and fulvestrant, the first of a new type of estrogen receptor antagonist that, unlike tamoxifen, has no partial agonist activity. The final results of the "Arimidex", Tamoxifen, Alone or in Combination (ATAC) trial, at a median follow-up of more than five years, and recent results from switching studies with anastrozole and exemestane, strengthen the position of these AIs as adjuvant treatment for hormone receptor-positive early breast cancer. Sequencing options for the future are also discussed because non-steroidal AIs are increasingly used early in the treatment sequence.
Authors
Howell, Anthony
Affiliation
CRUK Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. maria.parker@christie-tr.nwest.nhs.uk
Description
Date
2005-11
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Breast Cancer
Type
Article
Citation
New developments in the treatment of postmenopausal breast cancer. 2005, 16 (9):420-8 Trends Endocrinol. Metab.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/74875
Embedded videos